Correlation analysis of hormone receptors and the expressions of HER-2 and Ki-67 in breast cancer

Objective: This study aims to investigate the correlation and clinical significance of hormone receptors and the expressions of HER-2 and Ki-67 in breast cancer primary lesions and lymph node metastatic tissues. Methods: 83 cases were studied, who were performed breast cancer surgeries and confirmed the ipsilateral axillary lymph node metastasis by the postoperative pathological diagnosis. Immunohistochemical method was used to simultaneously detect the expressions of ER, PR, HER-2 and Ki-67 in the primary lesions and lymph node metastases. Results: ER exhibited the expression concordance rate as 85.5% in primary lesions and metastases, with significant difference (P = 0.039); the expression concordance rates of PR and HER-2 in primary lesions and metastases were 90.4% and 89.2%, respectively, without significant difference (P = 0.289, 0.180); between the Ki-67-highly-expressed primary lesions and Ki-67-lowly-expressed metastases, the expressions of ER in primary lesions and metastases exhibited statistical significance, with P as 0.031. Conclusions: The primary lesions and lymph node metastases had higher consistency, while there was still about 10% patients showed differentiated expression. The simultaneous detection of breast cancer primary lesions and lymph node metastases was still very necessary.

breast cancer; ER; PR; HER-2; Ki-67; immunohistochemistry; correlation analysis.

[1] Tzahar E., Waterman H., Chen X., Levkowitz G., Karunagaran D., Lavi S., et al.: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/ neuregulin and epidermal growth factor. Mol. Cell. Biol., 1996, 16, 5276.

[2] Yarden Y., Sliwkowski M.X.: Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol., 2001, 2, 127.

[3] Kruser T.J., Wheeler D.L.: Mechanisms of resistance to HER family targeting antibodies. Exp. Cell Res., 2010, 316, 1083.

[4] Mountzios G., Sanoudou D., Syrigos KN.: Clinical pharmacogenetics in oncology: the paradigm of molecular targeted therapies. Curr. Pharm. Des., 2010, 16, 2184.

[5] Hull DF 3rd., Clark G.M., Osborne C.K., Chamness G.C., Knight W.A. 3rd., McGuire W.L.: Multiple estrogen receptor assays in human breast cancer. Cancer Res., 1983, 43, 413.

[6] Lower E.E., Glass E.L., Bradley D.A., Blau R., Heffelfinger S.: Impact of metastatic estrogen receptor and progesterone receptor status on survival. Breast Cancer Res. Treat., 2005, 90, 65.

[7] Mobbs B.G., Fish E.B., Pritchard K.I., Oldfield G., Hanna W.H.: Estrogen and progesterone receptor content of primary and secondary breast carcinoma: influence of time and treatment. Eur. J. Cancer Clin. Oncol., 1987, 23, 819.

[8] Franco A., Col N., Chlebowski R.T.: Discordance in estrogen (ER) and progestin receptor (PR) status between primary metastatic breast cancer: a meta-analysis. J. Clin. Oncol., (Meeting Abstracts) 2004, 22, 539.

[9] Gross G.E., Clark G.M., Chamness G.C., McGuire W.L.: Multiple progesterone receptor assays in human breast cancer. Cancer Res., 1984, 44, 836.

[10] Zidan J., Dashkovsky I., Stayerman C., Basher W., Cozacov C., Hadary A.: Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. British J. Cancer, 2005, 93, 552.

[11] Masood S., Bui M.M.: Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann. Clin. Lab. Sci., 2000, 30, 259.

[12] Gong Y., Booser D. J., Sneige N.: Comparison of HER - 2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer, 2005, 103, 1763.

[13] Gancberg D., Di Leo A., Cardoso F., Rouas G., Pedrocchi M., Paesmans M., et al.: Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol., 2002, 13, 1036.

[14] Lower E.E., Glass E., Blau R., Harman S.: HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res. Treat., 2009, 113, 301.

[15] Arapantoni-Dadioti P., Valavanis C., Gavressea T., Tzaida O., Trihia H., Lekka I.: Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. J. BUON, 2012, 17, 277.

[16] Kontzoglou K., Palla V., Karaolanis G., Karaiskos I., Alexiou I., Pateras I., et al.: Correlation between Ki67 and breast cancer prognosis. Oncol., 2013, 84, 219.

[17] Ibrahim T., Farolfi A., Scarpi E., Mercatali L., Medri L., Ricci M., et al.: Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and pairedmetastases: clinical impact. Oncol., 2013, 84, 150. [18] Marsh K.L., Varley J.M.: Frequent alteration of cell cycle regulation early-stage breast lesions as detected by immunohistochemistry. Br. J. Cancer, 1998, 77, 1460.

[19] Goldhirsch A., Wood W.C., Coates A.S., Gelber R.D., ThürlimannB., Senn H.J.: Strategies for subtypes- dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Cnsensus on the Primary Therapy of Early Breast Cancer 2011. Ann. Oncol., 2011, 22, 1736.

[20] Harris L., Fritsche H., Mennel R., Norton L., Ravdin P., Taube S., et al.: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol., 2007, 25, 5287.

[21] Early Breast Cancer Trialists’Collaborative Group (EBCTCG), Davies C., Godwin J., Gray R., Clarke M., Cutter D., et al.: Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials. Lancet, 2011, 378, 771.

[22] Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., et al.: Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med., 2011, 365, 1273-83.

[23] Deng Z.P., Zhu J., Ma N.P., Song Z.J., Wang C.T., Wang Y., et al.: Discordance of the Expression of ER, PR and Her-2 receptor statuses between primary breast cancer and recurrent focuses. Journal of Modern Oncoligy, 2011, 19, 1562-4.

[24] Zhao H.B., Cheng X.Y., Liu J.J.: Control study of ER, PR and cerbB- 2 statuses between pri mary and metastatic axillarylymphnodes of breast cancer. Chinese Journal of Cancer Prevention and Treatment, 2011, 18, 594.

[25] Monaco S.E, Wu Y., Teot L.A., Cai G.: Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas. Diagn. Cytopathol., 2013, 41, 308.

[26] Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch. Pathol. Lab. Med., 2007, 131, 18.

[27] Yerushalmi R., Woods R., Ravdin P.M., Hayes M.M., Gelmon K.A.: Ki-67 in breast cancer: prognostic and predictive potential. Lancet Oncol., 2010, 11, 174.

[28] Tawfik K., Kimler B.F., Davis M.K., Fan F., Tawfik O.: Ki-67 expression in axillary lymph node metastases in breast cancer is prognostically significant. Hum. Pathol., 2013, 44, 39.